JP2023539341A5 - - Google Patents
Info
- Publication number
- JP2023539341A5 JP2023539341A5 JP2023514067A JP2023514067A JP2023539341A5 JP 2023539341 A5 JP2023539341 A5 JP 2023539341A5 JP 2023514067 A JP2023514067 A JP 2023514067A JP 2023514067 A JP2023514067 A JP 2023514067A JP 2023539341 A5 JP2023539341 A5 JP 2023539341A5
- Authority
- JP
- Japan
- Prior art keywords
- double
- stranded sirna
- section
- stranded
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073304P | 2020-09-01 | 2020-09-01 | |
| US63/073,304 | 2020-09-01 | ||
| PCT/US2021/048611 WO2022051332A1 (en) | 2020-09-01 | 2021-09-01 | Dux4 inhibitors and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539341A JP2023539341A (ja) | 2023-09-13 |
| JP2023539341A5 true JP2023539341A5 (enExample) | 2024-08-23 |
Family
ID=80492176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514067A Pending JP2023539341A (ja) | 2020-09-01 | 2021-09-01 | Ｄｕｘ４阻害剤およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230348906A1 (enExample) |
| EP (1) | EP4208548A4 (enExample) |
| JP (1) | JP2023539341A (enExample) |
| AR (1) | AR123420A1 (enExample) |
| AU (1) | AU2021337595A1 (enExample) |
| CA (1) | CA3189861A1 (enExample) |
| TW (1) | TW202227626A (enExample) |
| WO (1) | WO2022051332A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2021188390A1 (en) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| KR20230023612A (ko) | 2020-04-02 | 2023-02-17 | 마이레큘, 인크. | 조작된 올리고뉴클레오티드를 사용한 표적화된 억제 |
| CA3189065A1 (en) | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| WO2023185946A1 (zh) * | 2022-03-30 | 2023-10-05 | 苏州瑞博生物技术股份有限公司 | 一种寡核苷酸缀合物、含有该寡核苷酸缀合物的组合物及制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| EP3192880B1 (en) * | 2010-08-18 | 2019-10-09 | Fred Hutchinson Cancer Research Center | Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd) |
| EP2736539B1 (en) * | 2011-07-25 | 2017-08-23 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| US10538763B2 (en) * | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
| AU2018345772B2 (en) * | 2017-10-02 | 2025-04-17 | Research Institute At Nationwide Children's Hospital | MiRNA detargeting system for tissue specific interference |
| CN120247995A (zh) * | 2018-05-30 | 2025-07-04 | 诺华股份有限公司 | 脂质修饰的核酸化合物和方法 |
| WO2020028134A1 (en) * | 2018-07-30 | 2020-02-06 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating cancer |
| SG11202100928QA (en) * | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
-
2021
- 2021-09-01 CA CA3189861A patent/CA3189861A1/en active Pending
- 2021-09-01 AR ARP210102453A patent/AR123420A1/es unknown
- 2021-09-01 TW TW110132422A patent/TW202227626A/zh unknown
- 2021-09-01 US US18/043,520 patent/US20230348906A1/en active Pending
- 2021-09-01 WO PCT/US2021/048611 patent/WO2022051332A1/en not_active Ceased
- 2021-09-01 AU AU2021337595A patent/AU2021337595A1/en active Pending
- 2021-09-01 JP JP2023514067A patent/JP2023539341A/ja active Pending
- 2021-09-01 EP EP21865016.6A patent/EP4208548A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539341A5 (enExample) | ||
| TWI880645B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| US20160201063A1 (en) | Epigenetic regulators of frataxin | |
| JP2025504863A (ja) | タンパク質ＬＰＡ（Ａｐｏ（ａ））の発現を阻害するための組成物及び方法 | |
| EP3272868A1 (en) | Organic compositions to treat kras-related diseases | |
| AU2017290231A1 (en) | Exon skipping oligomers for muscular dystrophy | |
| JP2023538284A (ja) | Ｐｌｐ１発現を阻害するための組成物及び方法 | |
| JP2023539341A (ja) | Ｄｕｘ４阻害剤およびその使用方法 | |
| TW202321452A (zh) | 用於抑制血管生成素樣３（ａｎｇｐｔｌ３）蛋白表達的組合物和方法 | |
| CN118202049A (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| KR20240111795A (ko) | B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법 | |
| JP2023526328A5 (enExample) | ||
| WO2026026776A1 (zh) | 抑制APP基因表达的siRNA及其缀合物和应用 | |
| CN118202053A (zh) | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 | |
| JP2025504474A5 (enExample) | ||
| CN115137742A (zh) | 一种用于治疗肥胖症的rna递送系统 | |
| US7671035B2 (en) | Epidermal growth factor receptor antisense oligonucleotides | |
| JP2004528851A6 (ja) | 上皮成長因子受容体のアンチセンスオリゴヌクレオチド | |
| WO2026026592A1 (zh) | 抑制MAPT基因表达的siRNA及其缀合物和应用 | |
| WO2026050125A1 (en) | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder | |
| WO1998049287A2 (en) | Antisense oligonucleotides specific for thymidylate synthase | |
| WO2025090254A1 (en) | Adnp syndrome antisense treatment | |
| TW202345873A (zh) | 調節ｓｃａｐ活性之組合物及方法 | |
| WO2022206821A1 (zh) | 一种用于治疗帕金森的rna递送系统 | |
| WO2024169907A1 (zh) | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 |